ArticlePhysiological reports2025
Inflammatory and vascular biomarkers as predictors of all-cause death and cardiovascular outcomes in an Australian community-based cohort.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory and vascular biomarkers as predictors of all-cause death and cardiovascular outcomes in an Australian community-based cohort.Physiological reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biomarkers that identify individuals who are at higher risk of cardiovascular outcomes will allow for early intervention, lowering the incidence of adverse outcomes. This study investigated whether circulating levels of GDF-15, E-selectin, CD14, and ST2 are predictors of death and cardiovascular outcomes in 981 individuals who did not have a history of cardiovascular disease (CVD) during follow-up periods of 5, 10, and 20 years. During the 20-year follow-up, there were 389 deaths (including 147 from CVD), 105 participants had acute coronary syndrome (ACS), and 467 people had major adverse coronary and cerebrovascular events (MACCE) (including all-cause death). In the fully adjusted model, sE-selectin (5-year HR, 3.03; 95% CI 1.31-7.01), sCD14 (5 years 3.11; 1.02-9.45 and 10 years 2.52; 1.23-5.16), and sGDF-15 (10 years 2.07; 1.13-3.78 and 20 years 1.79; 1.24-2.56) predicted all-cause death. sE-selectin (5 years 2.19; 1.13-4.26), sCD14 (10 years 2.00; 1.08-3.68), and sGDF-15 (10 years 1.95; 1.18-3.22 and 20 years 1.53; 1.11-2.12) predicted MACCE. sGDF-15 predicted ACS at 5 (4.44; 1.01-19.49), 10 (2.86; 1.08-7.57) and 20 years (2.57; 1.31-5.04). High serum levels of sE-selectin, sGDF-15, and sCD14 at baseline are important independent risk factors for all-cause death and cardiovascular outcomes in a population without prevalent CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.